Topic resource collection
Approved comparison material connected to this topic.
20 resourcesRead both sides
Cathelicidin peptide LL-37 and defensins are both host defence peptides involved in innate immune protection [3], [5]. LL-37 is the major human cathelicidin-derived peptide, while defensins are a separate family with different st…
Peptide antibiotic concepts aim to use antimicrobial peptides or peptide-derived molecules as anti-infective tools, but development has been challenging because peptides can be unstable, costly to manufacture, degraded by proteas…
Approved use means a regulator has reviewed a specific product for a specific indication and labeling. Investigational research means a compound is being studied and may not have established safety, efficacy, manufacturing standa…
LL-37 may reduce some inflammatory responses, such as certain lipopolysaccharide-driven pathways, while enhancing immune activation in other settings by forming complexes with host DNA or RNA [15], [16], [17]. This context-depend…
Many people look at LL-37 next to other immune peptides. The three below get compared often because they show up in similar conversations. LL-37 cathelicidin signal + antimicrobial peptide recurrent infections, stubborn biofilm p…
LL-37 Local irritation, mild systemic reactions Immune system reactions Thymosin Alpha-1 Flu-like symptoms Rare autoimmune exacerbation This table highlights the need for individualized consideration of peptide therapies based on…
Magainin-2 vs LL-37 — Peptide Comparison Magainin-2 vs LL-37 — compare dosing, benefits, safety profiles, side effects, and how they stack. See which peptide is right for you. At a Glance Dose Range Magainin-2 1–5 mg LL-37 0.5–1.…
Lactoferricin B vs LL-37 — Peptide Comparison Lactoferricin B vs LL-37 — compare dosing, benefits, safety profiles, side effects, and how they stack. See which peptide is right for you. At a Glance Dose Range Lactoferricin B 1–10…
Cathelicidin (hCAP-18 / Synthetic Derivatives) vs LL-37 — Peptide Comparison Cathelicidin (hCAP-18 / Synthetic Derivatives) vs LL-37 — compare dosing, benefits, safety profiles, side effects, and how they stack. See which peptide…
PNC-27 vs LL-37 — Peptide Comparison PNC-27 vs LL-37 — compare dosing, benefits, safety profiles, side effects, and how they stack. See which peptide is right for you. At a Glance Dose Range PNC-27 1–2 mg LL-37 0.5–1.6 mg/mL (top…
Defensin (HBD-3) vs LL-37 — Peptide Comparison Defensin (HBD-3) vs LL-37 — compare dosing, benefits, safety profiles, side effects, and how they stack. See which peptide is right for you. At a Glance Dose Range Defensin (HBD-3) 1…
Human plasma (in vivo) 90–120 minutes Renal filtration + protease cleavage (elastase, proteinase-3) N/A. Endogenous clearance Short half-life is intentional regulatory mechanism to prevent sustained inflammation Lyophilised powde…
The table below clarifies when name changes reflect actual structural differences versus descriptive labeling. Critical for avoiding specification errors during procurement. LL-37 37 residues Reference sequence Full antimicrobial…
Understanding how LL37 and LL-37 appear across published research clarifies that the nomenclature difference is purely stylistic. The table below compares how each name variation is used in peer-reviewed literature, regulatory da…
The following table clarifies why 'cathelicidin' alone is insufficient for research peptide specifications. Sequence and bioactivity differ across species despite conserved precursor structure. | Species | Precursor Protein | Act…
Dose Range Magainin-2 1–5 mg LL-37 0.5–1.6 mg/mL (topical) Frequency Multiple times daily Once daily Administration Topical application (primary clinical route) Topical application (wound healing) Cycle Length 4-6 weeks 12+ weeks…
Dose Range Lactoferricin B 1–10 mg LL-37 0.5–1.6 mg/mL (topical) Frequency Multiple times daily Once daily Administration Oral (research — resistant to gastric digestion) Topical application (wound healing) Cycle Length 4-6 weeks…
Dose Range Defensin (HBD-3) 1–50 μg/mL (research) LL-37 0.5–1.6 mg/mL (topical) Frequency As needed Once daily Administration Topical application (research/wound care) Topical application (wound healing) Cycle Length Ongoing/inde…
Dose Range Cathelicidin (hCAP-18 / Synthetic Derivatives) 0.5–5 mg LL-37 0.5–1.6 mg/mL (topical) Frequency Once daily Administration Topical application (primary research route) Topical application (wound healing) Cycle Length 4-…
Dose Range PNC-27 1–2 mg LL-37 0.5–1.6 mg/mL (topical) Frequency Once daily Administration Subcutaneous injection Topical application (wound healing) Cycle Length 4-6 weeks 12+ weeks Onset Speed Rapid (hours to days) Moderate (1-…